Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations.
Marina Sáez-BellóVictor Mangas SanjuanMª Amparo Martínez-GómezMª Ángeles López-Montenegro SoriaMónica Climente-MartíMatilde Merino-SanjuánPublished in: British journal of clinical pharmacology (2020)
The population pharmacokinetic/pharmacodynamic model characterized the time course of capecitabine and its metabolites in plasma. Dose recommendations of capecitabine in patients with mutated and wild allele for single nucleotide polymorphisms rs2271862 of ≤3000 and ≤2400 mg/m2 /24 h in monotherapy and ≤1750 and ≤600 mg/m2 /24 h in combination with oxaliplatin, respectively, have been proposed.
Keyphrases
- phase ii study
- end stage renal disease
- locally advanced
- metastatic breast cancer
- metastatic colorectal cancer
- ejection fraction
- phase iii
- newly diagnosed
- chronic kidney disease
- open label
- prognostic factors
- ms ms
- peritoneal dialysis
- randomized controlled trial
- clinical trial
- patient reported outcomes
- rectal cancer
- study protocol
- genetic diversity